<DOC>
	<DOCNO>NCT01024764</DOCNO>
	<brief_summary>The result Phase I Safety Immunogenicity Trial Recombinant HIV-1 Tat ( ISS P-001 ISS T-001 ) indicate vaccine base recombinant Tat protein safe , well tolerate immunogenic . The present study intend extend follow-up volunteer additional 3 year evaluate persistence anti-Tat humoral cellular immune response . The result present study key design future phase II trial , particularly definition optimal schedule boost immunization . All individual ( 20 ) enrol 120-weeks observational study monitor every 24 week follow 3 year . During visit , addition hematological biochemical assessment , anti-Tat specific humoral cellular immune response evaluate .</brief_summary>
	<brief_title>Observational Study Preventive Trial With HIV-1 Tat Protein</brief_title>
	<detailed_description />
	<criteria>Previous participation Phase I Clinical Trial ISS P001</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>Tat protein</keyword>
	<keyword>Preventive vaccine</keyword>
</DOC>